← Back to Search

Bias Reduction Training for Rheumatic Diseases

N/A

Waitlist Available

Led By Candace H Feldman, MD, ScD

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months following the encounter of interest

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if a provider-based intervention can improve care for Black/African American and lower socioeconomic status patients with rheumatic diseases.

Who is the study for?

This trial is for English-speaking Black or African American adults, or those with low socioeconomic status indicated by Medicaid/Mass Health insurance. Participants must be diagnosed with SLE or inflammatory arthritis like RA, have visited the provider less than twice in the past year, and be able to consent. Rheumatologists participating need at least one clinical session per week.

What is being tested?

The study tests an individuation intervention combined with implicit bias education aimed at improving rheumatic disease care quality for certain demographics. It also examines how this approach affects communication between providers and patients, treatment adherence, trust in providers, and satisfaction with care.

What are the potential side effects?

Since this trial focuses on educational modules and behavioral interventions rather than medications, traditional physical side effects are not applicable. However, participants may experience discomfort discussing personal biases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months following the encounter of interest

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months following the encounter of interest

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months following the encounter of interest for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percent of patients receiving high quality care

Secondary study objectives

Adherence

Everyday Discrimination Scale

Implicit Association Test (IAT) scores

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm 1: Individuation Intervention plus implicit bias educationExperimental Treatment2 Interventions

10 rheumatologists who will have 10 patient interactions each (100 patients total) recorded Rheumatologists will watch implicit bias training modules and then will be instructed to incorporate an individuation strategy into each of their clinical encounters.

Group II: Arm 2: Implicit bias education onlyActive Control1 Intervention

10 rheumatologists randomized and stratified by hospital and gender

Do I qualify?Apply below to find out